Raynaud's phenomenon

Vascular Medicine

Volumn , Issue , 2006, Pages 689-705

  Creager, Mark A ^a,b,c   Halperin, Jonathan L ^d,e   Coffman, Jay D ^f,g  

^a HARVARD MEDICAL SCHOOL   (United States)

^b Cardiovascular Medicine   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^e MOUNT SINAI MEDICAL CENTER   (United States)

^f BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g BOSTON MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882548944     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-7216-0284-4.50054-3     Document Type: Chapter

References (137)

1. Raynaud M L'Asphyxie Locale et de la Gangrene Symmetrique des Extremities 1862, New Sydenham Society, London. T. Barlow (Ed.).
2. Coffman JD Raynaud Phenomenon 1989, Oxford University Press, New York.
3. Wigley FM Raynaud's phenomenon. N Engl J Med 2002, 347:1001.
4. Coffman JD Raynaud's phenomenon. Curr Opin Cardiol 1993, 8:821.
5. Maricq HR, Weinrich MC, Keil JE, et al. Prevalence of Raynaud's phenomenon in the general population. J Chronic Dis 1986, 38:423.
6. Allen EV, Brown GE Raynaud's disease: A critical review of minimal requisites for diagnosis. Am J Med Sci 1932, 183:187.
7. LeRoy EC, Medsger TA Raynaud's phenomenon: A proposal for classification. Clin Exp Rheumatol 1991, 10:485.
8. Gifford RW, Hines EA Raynaud's disease among women and girls. Circulation 1957, 16:1012.
9. Guntheroth WG, Morgan BC, Harbinson JA, et al. Raynaud's disease in children. Circulation 1967, 36:724.
10. Maricq HR, Carpentier PH, Weinrich MC, et al. Geographic variation in prevalence of Raynaud's phenomenon. Charleston, SC, USA vs Tarentaise, Savoie France. J Rheumatol 1993, 20:70.
11. Freedman RR, Mayes MD Familial aggregation of primary Raynaud's disease. Arthritis Rheum 1996, 39:1189.
12. Miller D, Waters DD, Warnica W, et al. Is variant angina the coronary manifestation of a generalized vasospastic disorder?. N Engl J Med 1981, 304:763.
13. Zahavi I, Chagnac A, Hering R, et al. Prevalence of Raynaud's phenomenon in patients with migraine. Arch Intern Med 1984, 144:742.
14. O'Keeffe ST, Tsapatsaris NP, Beetham WP Increased prevalence of migraine and chest pain in patients with primary Raynaud disease. Ann Intern Med 1992, 116:985.
15. Cannon PJ, Hassar M, Case DB, et al. The relationship of hypertension and renal failure in scleroderma (progressive systemic sclerosis) to structural and functional abnormalities of the renal cortical circulation. Medicine 1974, 53:1.
16. Salmenson BD, Reisman J, Sinclair SH, et al. Macular capillary hemodynamic changes associated with Raynaud's phenomenon. Ophthalmology 1992, 99:914.
17. Vergnon J-M, Barthelemy JC, Riffat J, et al. Raynaud's phenomenon of the lung. Chest 1992, 101:1312.
18. Krumholz HM, Goldberger AL Systemic arterial vasospastic syndrome: Familial occurrence with variant angina. Am J Med 1992, 92:344.
19. Coffman JD, Cohen RA Vasospasm-ubiquitous?. N Engl J Med 1981, 304:780.
20. Tokola R, Hokkanen E Propranolol for acute migraine. Br Med J 1978, 2:1089.
21. Yasue H, Youyama M, Shimamoto M, et al. Role of autonomic nervous system in the pathogenesis of Prinzmetal's variant form of angina. Circulation 1974, 50:534.
22. Marshal AJ, Roberts CJC, Barritt DW Raynaud's phenomenon as side effect of β-blockers in hypertension. Br Med J 1976, 1:1498.
23. Schroeder JS, Bolen JL, Quint RA, et al. Provocation of coronary spasm with ergonovine maleate: New test with results in 57 patients undergoing coronary arteriography. Am J Cardiol 1977, 40:487.
24. Curry RC, Pepine CJ, Sabom MB, et al. Effects of ergonovine in patients with and without coronary artery disease. Circulation 1977, 56:803.
25. Wollersheim H, Thien T, Hoet MH, et al. The diagnostic valve of several immunological tests for anti-nuclear antibody in predicting the development of connective tissue disease in patients presenting with Raynaud's phenomenon. Eur J Clin Invest 1989, 19:535.
26. Cohen RA, Coffman JD Digital vasospasm: The pathophysiology of Raynaud's phenomenon. Int Angiology 1984, 3:47.
27. Lewis T Experiments relating to the peripheral mechanism involved in spasmodic arrest of the circulation in the fingers, a variety of Raynaud's disease. Heart 1929, 15:7.
28. Freedman RR, Mayes MD, Sabharwal SC Induction of vasospastic attacks despite digital nerve block in Raynaud's disease and phenomenon. Circulation 1989, 80:859.
29. Jamieson GG, Ludbrook J, Wilson A Cold hypersensitivity in Raynaud's phenomenon. Circulation 1971, 44:254.
30. Vanhoutte PM, Cooke JP, Lindblad LE, et al. Modulation of postjunctional α-adrenergic responsiveness by local changes in temperature. Clin Sci 1985, 68:121s.
31. Cooke JP, Shepherd JT, Vanhoutte PM The effect of warming on adrenergic neurotransmission in canine cutaneous vein. Circ Res 1984, 54:547.
32. Flavahan NA, Cooke JP, Shepherd JT, et al. Human postjunctional alpha-1 and alpha-2 adrenoceptors: Differential distribution in arteries of the limbs. J Pharmacol ExpTher 1987, 241:361.
33. 2-adrenoceptors in human vascular smooth muscle cells. Am J Physiol Heart Circ Physiol 2004, 286:H59.
34. 2C-adrenoceptors from Golgi to plasma membrane in transfected human embryonic kidney 293 cells. Mol Pharmacol 2001, 60:1195.
35. Keenan EJ, Porter JM Alpha-2-adrenergic receptors in platelets from patients with Raynaud's syndrome. Surgery 1983, 94:204.
36. Coffman JD, Cohen RA Role of alpha-adrenoceptor subtypes mediating sympathetic vasoconstriction in human digits. Eur J Clin Invest 1988, 18:309.
37. 2 receptor hypersensitivity in Raynaud's phenomenon. J Vasc Med Biol 1990, 2:100.
38. Cooke JP, Creager SJ, Scales KM, et al. Role of digital artery adrenoceptors in Raynaud's disease. Vasc Med 1997, 2:1.
39. Peacock JH Peripheral venous blood concentrations of epinephrine and norepinephrine in primary Raynaud's disease. Circ Res 1959, 7:821.
40. Kontos HA, Wasserman AJ Effect of reserpine in Raynaud's phenomenon. Circulation 1969, 39:259.
41. Downey JA, Leroy EC, Miller JM, et al. Thermoregulation and Raynaud's phenomenon. Clin Sci 1971, 40:211.
42. Fagius J, Blumberg H Sympathetic outflow to the hand in patients with Raynaud's phenomenon. Cardiovasc Res 1985, 19:249.
43. Greenblatt DJ, Koch-Weser J Adverse reactions to beta-adrenergic receptor blocking drugs. A report from the Boston Collaborative Drug Surveillance Program. Drugs 1974, 7:118.
44. Marshall AJ, Roberts CJC, Barritt DW Raynaud's phenomenon as side effect of beta-blockers in hypertension. Br Med J 1976, 1:1498.
45. Eliasson K, Lins LE, Sundqvist K Peripheral vasospasm during beta receptor blockade-a comparison between metoprolol and pindolol. Acta Med Scand Suppl 1982, 665:109.
46. Cohen RA, Coffman JD Beta-adrenergic vasodilator mechanism in the finger. Circ Res 1981, 49:1196.
47. Vanhoutte PM 5-Hydroxytryptamine and vascular disease. Fed Proc 1983, 42:233.
48. Vanhoutte PM, Shepherd JT Effect of temperature on reactivity of isolated cutaneous veins of the dog. Am J Physiol 1970, 218:187.
49. Winkelmann RK, Goldyne ME, Linscheid RL Hypersensitivity of scleroderma cutaneous vascular smooth muscle to 5-hydroxytryptamine. Br J Dermatol 1976, 95:51.
50. Coffman JD, Cohen RA Serotonergic vasoconstriction in human fingers during reflex sympathetic response to cooling. Am J Physiol 1988, 254:H889.
51. Halpern A, Kuhn PH, Shaftel HE, et al. Raynaud's disease, Raynaud's phenomenon, and serotonin. Angiology 1960, 11:151.
52. Reimann IW, Frolich JC Mechanism of antihypertensive action of ketanserin in man. Br Med J 1983, 287:381.
53. Zabludowski JR, Ball SG, Robertson JIS Ketanserin and alpha1 adrenergic antagonism in humans. J Cardiovasc Pharmacol 1985, 7:S123.
54. Hechtman DH, Jageneau A Inhibition of cold-induced vasoconstriction with ketanserin. Microvasc Res 1985, 30:56.
55. Coffman JD, Clement DL, Creager MA, et al. International study of ketanserin in Raynaud's phenomenon. Am J Med 1989, 87:264.
56. 2) receptor. Arthritis Rheum 1984, 27:139.
57. Stranden E, Roald OK, Krohg K Treatment of Raynaud's phenomenon with the 5-HT2 receptor antagonist ketanserin. Br Med J 1982, 285:1069.
58. Roald OK, Seem E Treatment of Raynaud's phenomenon with ketanserin in patients with connective tissue disorders. Br Med J 1984, 289:577.
59. Coffman JD, Rasmussen HM Effect of thromboxane synthetase inhibition in Raynaud's phenomenon. Clin Pharmacol Ther 1984, 36:369.
60. Ettinger WH, Wise RA, Schaffhauser D, et al. Controlled double-blind trial of dazoxiben and nifedipine in the treatment of Raynaud's phenomenon. Am J Med 1984, 77:451.
61. Jones EW, Hawkey CJ A thromboxane synthetase inhibitor in Raynaud's phenomenon. Prostaglandins Leukot Med 1983, 12:67.
62. Luderer JR, Nicholas GG, Neumyer MM, et al. Dazoxiben, a thromboxane synthetase inhibitor in Raynaud's phenomenon. Clin Pharmacol Ther 1984, 36:105.
63. Tindall H, Tooke JE, Menys VC, et al. Effect of dazoxiben, a thromboxane synthetase inhibitor on skin blood flow following cold challenge in patients with Raynaud's phenomenon. Eur J Clin Invest 1985, 15:20.
64. Zamora MR, O'Brien RF, Rutherford RB, et al. Serum endothelin-1 concentrations and cold provocation in primary Raynaud's phenomenon. Lancet 1990, 336:1144.
65. Smyth AE, Bell AL, Bruce IN, et al. Digital vascular responses and serum endothelin-1 concentrations in primary and secondary Raynaud's phenomenon. Ann Rheum Dis 2000, 59:870.
66. Burton AC The physical equilibrium of the small blood vessels. Am J Physiol 1951, 164:319.
67. Krahenbuhl B, Nielsen SL, Lassen NA Closure of digital arteries in high vascular tone states as demonstrated by measurement of systolic blood pressure in the finger. Scand J Clin Lab Invest 1977, 37:71.
68. Landis EM Micro-injection studies of capillary blood pressure in Raynaud's disease. Heart 1930, 15:247.
69. Thulesius O Methods for evaluation of peripheral vascular function in the upper extremities. Acta Chir Scand 1976, 465(suppl):53.
70. Cohen RA, Coffman JD Reduced fingertip arterial pressure in Raynaud's disease. J Vasc Med Biol 1989, 1:21.
71. Brown GE, Griffin HZ Peripheral arterial disease in polycythemia vera. Arch Intern Med 1930, 46:705.
72. Imhof JW, Boars H, Verloop MC Clinical haematologic aspects of macroglobulinaemia Waldenström. Acta Med Scand 1959, 163:349.
73. Marshal RJ, Shepherd JT, Thompson ID Vascular responses in patients with high serum titres of cold agglutinins. Clin Sci 1953, 12:255.
74. McGrath MA, Penny R Blood hyperviscosity in cryoglobulinemia: temperature sensitivity and correlation with reduced skin blood flow. Aust J Exp Biol Med Sci 1978, 56:127.
75. Hillestad LK The peripheral circulation during exposure to cold in normals and in patients with the syndrome of high-titre cold haemagglutination. Acta Med Scand 1959, 164:211.
76. Jahnsen T, Nielsen SL, Skovborg F Blood viscosity and local response to cold in primary Raynaud's phenomenon. Lancet 1977, 2:1001.
77. Walder DN Blood viscosity and Raynaud's disease. J R Coll Surg Edinb 1973, 18:277.
78. McGrath MA, Peek R, Penny R Raynaud's disease: Reduced hand blood flows with normal blood viscosity. Aust N Z J Med 1978, 8:126.
79. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980, 23:581. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee.
80. Maricq HR, LeRoy EC, D'Angelo WA, et al. Diagnostic potential of in vivo capillary microscopy in scleroderma and related disorders. Arthritis Rheum 1980, 23:183.
81. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982, 25:1271.
82. Fischer M, Mielke H, Glaefke S, et al. Generalized vasculopathy and finger blood flow abnormalities in rheumatoid arthritis. J Rheum 1984, 11:33.
83. Arnett FC, Edworthy SM, Block DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988, 31:315.
84. Garcia-Carrasco M, Siso A, Ramos-Casals M, et al. Raynaud's phenomenon in primary Sjogren's syndrome. Prevalence and clinical characteristics in a series of 320 patients. J Rheumatol 2002, 29:726.
85. Waller DG, Dathan JR Raynaud's syndrome and carpal tunnel syndrome. Postgrad Med J 1985, 61:161.
86. Cooper RA, Bunn HF Hemolytic anemia. Harrison's Principles of Internal Medicine 1987, McGraw-Hill, New York. E. Braunwald (Ed.).
87. Trejo O, Ramos-Casals M, Garcia-Carrasco M, et al. Cryoglobulinemia: Study of etiologic factors and clinical and immunologic features in 443 patients from a single center. Medicine (Baltimore) 2001, 80:252.
88. Jager BV Cryofibrinogenemia. N Engl J Med 1962, 266:579.
89. Letz R, Cherniack MG, Gerr F, et al. A cross sectional epidemiological survey of shipyard workers exposed to hand-arm vibration. Br J Indust Med 1992, 49:53.
90. Mirbod SM, Yoshida H, Nagata C, et al. Hand-arm vibration syndrome and its prevalence in the present status of private forestry enterprises in Japan. Int Arch Occup Environ Health 1992, 64:93.
91. Davies TAL, Glaser EM, Collins CP Absence of Raynaud's phenomenon in workers using vibratory tools in warm climate. Lancet 1957, 1:1014.
92. Okada A, Inaba R, Furuno T Occurrence of intimal thickening of the peripheral arteries in response to local vibration. Br J Ind Med 1987, 44:470.
93. Hisanaga H Studies of peripheral nerve conduction velocities in vibrating tool operators. Sangyo Igaku 1982, 24:284.
94. Laplanche A, Clavel-Chapelon F, Contassot JC, et al. Exposure to vinyl chloride monomer: Results of a cohort study after a seven year follow up. The French VCM Group. Br J Ind Med 1992, 49:134.
95. Coffman JD, Rasmussen HM Effects of beta-adrenoceptor-blocking drugs in patients with Raynaud's phenomenon. Circulation 1985, 72:466.
96. Nielsen SL, Parving H-H, Hansen JEM Myxoedema and Raynaud's phenomenon. Acta Endocrinol (Copenh) 1989, 101:32.
97. Nielsen SL, Lokkegaard H Cold hypersensitivity and finger systolic blood pressure in hemodialysis patients. Scand J Urol Nephrol 1989, 15:319.
98. Preston IR, Hill NS Evaluation and management of pulmonary hypertension in systemic sclerosis. Curr Opin Rheumatol 2003, 15:761.
99. Fuster V, Steele PM, Edwards WD, et al. Primary pulmonary hypertension: Natural history and the importance of thrombosis. Circulation 1984, 70:580.
100. Rich S, Dantzker DR, Ayres SM, et al. Primary pulmonary hypertension. A national prospective study. Ann Intern Med 1987, 107:216.
101. Nielsen SL Raynaud's phenomena and finger systolic pressure with cooling. Scand J Clin Lab Invest 1978, 38:765.
102. Coffman JD Effect of propranolol on blood pressure and skin blood flow during cigarette smoking. J Clin Pharmacol 1969, 9:39.
103. Keefe FJ, Surwit RS, Pilon RN A 1-year follow-up of Raynaud's patients treated with behavioral therapy techniques. J Behav Med 1979, 2:385.
104. Keefe FJ, Surwit RS, Pilon RN Biofeedback, autogenic training, and progressive relaxation in the treatment of Raynaud's disease: A comparative study. J Appl Behav Anal 1980, 13:3.
105. Rich S, Dantzker DR, Ayres SM, et al. Primary pulmonary hypertension. A national prospective study. Ann Intern Med 1987, 107:216.
106. Yocum DE, Hodes R, Sundstrom WR, et al. Use of biofeedback training in treatment of Raynaud's disease and phenomenon. J Rheumatol 1985, 12:90.
107. Stambrook M, Hamel ER, Carter SA Training to vasodilate in a cooling environment: A valid treatment for Raynaud's phenomenon?. Biofeedback Self-Regul 1988, 13:9.
108. Guglielmi RS, Roberts AH, Patterson R Skin temperature biofeedback for Raynaud's disease: A double-blind study. Biofeedback Self-Regul 1982, 7:99.
109. Freedman RR, Ianni P, Wenig P Behavioral treatment of Raynaud's phenomenon in scleroderma. J Behav Med 1984, 7:343.
110. Comparison of sustained-release nifedipine and temperature biofeedback for treatment of primary Raynaud's phenomenon. Arch Intern Med 2000, 160:1101. Raynaud's Treatment Study Investigators.
111. Jobe JB, Sampson JB, Roberts DE, et al. Induced vasodilation as treatment for Raynaud's disease. Ann Intern Med 1982, 97:706.
112. Coffman JD Raynaud's phenomenon. Curr Ther Options Cardiovasc Med 2000, 2:219.
113. Belch JJF, Meilen H Pharmacotherapy of Raynaud's phenomenon. Drugs 1996, 52:682.
114. Antman EM, Stone PH, Muller JE, et al. Calcium channel blocking agents in the treatment of cardiovascular disorders. Part I: Basic and clinical electrophysiologic effects. Ann Intern Med 1980, 93:875.
115. Stone PH, Antman EM, Muller JE, et al. Calcium channel blocking agents in the treatment of cardiovascular disorders. II: Hemodynamic effects and clinical applications. Ann Intern Med 1980, 93:886.
116. Creager MA, Pariser KM, Winston EM, et al. Nifedipine-induced fingertip vasodilation in patients with Raynaud's phenomenon. Am Heart J 1984, 108:370.
117. Nilsson H, Jonason T, Leppert J, et al. The effect of the calcium-entry blocker nifedipine on cold-induced digital vasospasm. A double-blind crossover study versus placebo. Acta Med Scand 1987, 221:53.
118. Matucci Cerinic M, Falcini F, Bartolozzi G, et al. Nifedipine treatment of Raynaud's phenomenon in a paediatric age. Int J Clin Pharm Res 1985, 5:67.
119. Kahan A, Amor B, Menkes CJ A randomised double-blind trial of diltiazem in the treatment of Raynaud's phenomenon. Ann Rheum Dis 1985, 44:30.
120. Rhedda A, McCans J, Willan AR, et al. A double blind placebo controlled crossover randomized trial of diltiazem in Raynaud's phenomenon. J Rheumatol 1985, 12:724.
121. Matoba T, Chiba M Effects of diltiazem on occupational Raynaud's syndrome (vibration disease). Angiology 1985, 36:850.
122. Schmidt JF, Valentin N, Nielsen SL The clinical effect of felodipine and nifedipine in Raynaud's phenomenon. Eur J Clin Pharmacol 1989, 37:191.
123. Kallenberg CGM, Wouda AA, Meems L, et al. Once daily felodipine in patients with primary Raynaud's phenomenon. Eur J Clin Pharmacol 1991, 40:313.
124. Kinney EL, Nicholas GG, Gallo J, et al. The treatment of severe Raynaud's phenomenon with verapamil. J Clin Pharmacol 1982, 22:74.
125. Nielsen SL, Vitting K, Rasmussen K Prazosin treatment of primary Raynaud's phenomenon. Eur J Clin Pharmacol 1983, 24:421.
126. McFadyen IJ, Housley E, MacPherson AIS Intraarterial reserpine administration in Raynaud syndrome. Arch Intern Med 1973, 132:526.
127. LeRoy EC, Downey JA, Cannon PJ Skin capillary blood flow in scleroderma. J Clin Invest 1971, 50:930.
128. Varadi DP, Lawrence AM Suppression of Raynaud's phenomenon by methyldopa. Arch Intern Med 1969, 124:13.
129. Carter SA Finger systolic pressures and skin temperatures in severe Raynaud's syndrome: The relationship to healing of skin lesions and the use of oral phenoxybenzamine. Angiology 1981, 32:298.
130. Coleiro B, Marshall SE, Denton CP, et al. Treatment of Raynaud's phenomenon with the selective serotonin reuptake inhibitor fluoxetine. Rheumatology (Oxford) 2001, 40:1038.
131. Gresele P, Volpato R, Migliacci R, et al. Thromboxane does not play a significant role in acute, cold-induced vasoconstriction in Raynaud's phenomenon. Studies with combined thromboxane synthase inhibition and thromboxane receptor antagonism. Thromb Res 1992, 66:259.
132. Challenor VF Angiotensin converting enzyme inhibitors in Raynaud's phenomenon. Drugs 1994, 48:864.
133. Tosi S, Marchesoni A, Messina K, et al. Treatment of Raynaud's phenomenon with captopril. Drugs Exp Clin Res 1987, 13:37.
134. Dziadzio M, Denton CP, Smith R, et al. Losartan therapy for Raynaud's phenomenon and scleroderma: Clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial. Arthritis Rheum 1999, 42:2646.
135. Teh LS, Manning J, Moore T, et al. Sustained-release transdermal glyceryl trinitrate patches as a treatment for primary and secondary Raynaud's phenomenon. Br J Rheumatol 1995, 34:636.
136. Sambo P, Amico D, Giacomelli R, et al. Intravenous N-acetylcysteine for treatment of Raynaud's phenomenon secondary to systemic sclerosis: A pilot study. J Rheumatol 2001, 28:2257.
137. de Trafford JC, Lafferty K, Potter CE, et al. An epidemiological survey of Raynaud's phenomenon. Eur J Vasc Surg 1988, 2:167.